Systemic therapy for elderly patients with gastrointestinal cancer

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 89-99

  Hubbard, Joleen M ^a   Grothey, Axel ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Gastrointestinal cancers; Geriatric oncology; Neoadjuvant therapy; Perioperative therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LETHARGY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT COMPLIANCE; PREOPERATIVE TREATMENT; REVIEW; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79958022753     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6983     Document Type: Review

References (82)

1. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10: 198-204.
2. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
3. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. Jama. 303:1037-1045.
4. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.
5. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24: 2368-2375.
6. Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109:2410-2419.
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
8. Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist. 2008;13:390-402.
9. Rim SH, Seeff L, Ahmed F, King JB, Coughlin SS. Colorectal cancer incidence in the United States, 1999-2004: an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1967-1976.
10. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. Jama. 2005;294:2703-2711.
11. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
12. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349-357.
13. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-3116.
14. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). 2010 Gastrointestinal Cancers Symposium Abstract No: 284.
15. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-2204.
16. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24:4085-4091.
17. Jackson McCleary NA, Meyerhardt J, Green GYE., et al. Impact of older age on the efficacy of newer adjuvant therapies in.12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 27:15 s, 2009 (suppl; abstr 4010).
18. Hsiao FS, Mullins CD, Onukwugha E, Pandya NB, Seal BS, Hanna N. Relative survival of adjuvant chemotherapy using 5-FU/LV alone, oxaliplatin, or irinotecan-based combination regimens among stage III colon cancer patients age 65 and older: an analysis using SEER-Medicare data. In: 2010 Gastrointestinal Cancers Symposium.
19. Berretta M, Cappellani A, Fiorica F, et al. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Arch Gerontol Geriatr.
20. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
21. Rosati G, Cordio S, Tucci A, et al. Phase II trial of oxaliplatin and tegafur/ uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology. 2005;69:122-129.
22. Twelves CJ, Butts CA, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer. 2005;5: 101-107.
23. Seymour MT, Maughan TS, Wasan HS, et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18S (June 20 Supplement), 2007: 9030.
24. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394-400.
25. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-2012.
26. Grande C Sr, Quintero G, Candamio S, et al. Phase II study of biweekly capecitabine and oxaliplatin (XELOX) as first-line treatment in elderly patients with metastatic colorectal cancer. In: 2010 Gastrointestinal Cancers Symposium.
27. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355: 1041-1047.
28. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23:4856-4865.
29. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443-1451.
30. Falcone A, Loupakis S, Cupini F, et al. FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). In: 2010 ASCO Annual Meeting June 4-8, 2010, Chicago, IL.
31. Vamvakas L, Athanasiadis A, Karampeazis A, et al. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol. 2010;76:61-70.
32. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
33. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
34. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. In: 2010 ASCO Annual Meeting June 4-8, 2010; Chicago, IL. p. Abstract CRA3507.
35. Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67:255-262.
36. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26: 2008 (May 20 suppl; abstr 2).
37. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4000).
38. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
39. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
40. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
41. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute. 2007;99: 1232-1239.
42. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE Prospective Cohort Study. Gastrointestinal Cancers Symposium; 2008.
43. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute, 2010. (Accessed January 18, 2011, at http://seer.cancer.gov/csr/1975_2007/).
44. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
45. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297: 267-277.
46. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073-1081.
47. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59:2006-2010.
48. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region: Phase III Trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Annals of Surgery. 1999;230:776.
49. Neoptolemos JP, Stocken DD, Friess H, et al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. New England Journal of Medicine. 2004;350:1200-1210.
50. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026.
51. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710.
52. Morizane C, Okusaka T, Ito Y, et al. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients. Oncology. 2005;68:432-437.
53. Miyamoto DT, Mamon HJ, Ryan DP, et al. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010;77:1171-1177.
54. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
55. Locher C, Fabre-Guillevin E, Brunetti F, et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol. 2008;68:178-182.
56. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
57. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive careversus best supportive care alone (BSC) in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003). In: 2005 ASCO Annual Meeting.
58. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. In: 2010 ASCO Annual Meeting.
59. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-5067.
60. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. In: 2007 ASCO Annual Meeting.
61. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
62. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
63. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357: 1810-1820.
64. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-1064.
65. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608.
66. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837-843.
67. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303: 1729-1737.
68. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
69. Tepper JE, Krasna M, Niedzwiecki D, et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. In: 2006 ASCO Annual Meeting.
70. Rice DC, Correa AM, Vaporciyan AA, et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005;79:391-397, discussionn -7.
71. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. In: 46th ASCO Annual Meeting; June 4-8, 2010, Chicago, IL.
72. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010:CD004064.
73. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
74. Shah MA, Stoller R, Shibata S, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). In: 2010 Gastrointestinal Cancers Symposium.
75. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358: 36-46.
76. Jatoi A, Foster NR, Egner J, et al. Elderly patients with metastatic esophageal/ gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials. In: 44th ASCO Annual Meeting Chicago, IL, 30th May-3rd June 2008.
77. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-221.
78. Narahara H, Fujitani K, Takiuchi H, et al. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74:37-41.
79. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-1069.
80. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-1553.
81. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376: 687-697.
82. Extermann M. Geriatric oncology: an overview of progresses and challenges. Cancer Res Treat. 2010;42:61-68.